abbvi post steadi offer slightli disappoint
outlook share look under-valued
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
hold strong portfolio market pipelin
drug increas competit compani key drug humira
slow growth compani total sale
higher portion earn due higher margin revenu
humira key determin perform next
approv rheumatoid arthriti psoriasi crohn
diseas humira continu grow market
penetr rate averag long-term
challeng emerg despit favor near-term outlook
humira uncertainti around encroach competit
like weigh investor sentiment toward compani
particular new jak inhibitor antibodi repres
major drug advanc rheumatoid arthriti psoriasi
like lead market share loss humira also
humira biolog composit longer-last patent
may deter gener complet follow key patent
loss patent loss europ model close
annual revenu declin humira
well-posit next gener immunolog drug
particular pipelin drug shown improv efficaci safeti
humira current lead treatment option
beyond immunolog cancer drug imbruvica next-biggest
sale contributor imbruvica strong clinic data sever form
blood cancer lead peak sale billion
remain drug larg matur patent expir long
past manufactur specif dose complex
look forward pipelin weight heavili toward new
cancer drug particular pipelin lead
increasingli strong posit blood cancer compani
abl leverag solid entrench imbruvica launch
new drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note earn per share calcul use earn divid share
drug compani strong exposur immunolog
oncolog compani top drug humira repres half
compani current profit compani spun abbott earli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbvi post steadi offer slightli
disappoint outlook share look
along fourth-quart result larg met
expect slightli under-perform consensu
project expect meaning
chang fair valu estim howev
guidanc oncolog drug venclexta endometriosi
drug orilissa slightli behind project
continu expect drug develop major sale
contributor sale estim billion
competit testosteron therapi androgel weigh
howev sale declin expect
humira intern due biosimilar line
manag guidanc despit headwind
reason well posit new drug
mitig gener pressur affect humira
long term support narrow moat rate
howev lack convict award wide moat rate
given higher level uncertainti offset gener
humira pressur drug repres close
quarter intern humira sale fell year
year expect declin acceler
expect humira face price volum
eros close expect
biosimilar launch remain intern
countri lead project declin
expect largest gener headwind
biosimilar like enter unit state
launch sever new drug help
blockbust potenti immunolog drug risankizumab
upadacitinib launch
current launch hematolog drug imbruvica
venclexta grow significantli base new
indic excel efficaci
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
fair valu estim stand model
annual humira declin begin outsid
 follow key patent settlement
key valuat driver off-set eventu like humira sale
declin compani next-gener immunolog
drug target jak pathway new
pathway seem offer better efficaci improv
side effect profil humira help off-set like
strong blockbust potenti leukemia also compani
sever late-stag cancer drug
help mitig eventu humira sale declin
billion total sale project slightli
manag guidanc billion bottom
line next three year expect improv margin
larg driven higher contribut total sale
specialti drug carri high margin also
partnership royalti humira began expir
help improv gross margin weight
averag cost capit use cost equiti
market rate cost debt
larg base low volatil cash flow
divers inelast product portfolio rate
uncertainti medium slightli higher
pharma peer group partli due high product
concentr risk surround humira half total
estim bull case probabl
bear case probabl project fair
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
humira sale declin begin rate
declin like gradual typic small
molecule-brand drug face gener competit
complex develop market biosimilar
nevertheless deriv enorm cash flow
current product portfolio fund on-going discoveri
develop next gener drug larg cash
flow creat economi scale enabl
fund averag million requir new drug
strong pharma firm
creat databas intellectu insight help
increas odd success drug develop final
entrench salesforc one
sought-aft therapeut area immunolog help
firm launch next gener drug make
compani lead candid smaller drug firm need
help develop commerci innov new drug
moat trend neg sever competit
threat target humira new brand drug
launch humira key therapeut area includ
ra psoriasi crohn diseas howev
expect humira lose high degre market share
new drug slow market eros longer term
like addit humira patent
loss like bring new competit threat gener
manufactur damag partli mitig given
biolog complex manufactur market
gener version drug also less power patent
like delay competit case
agre launch
less-pow patent keep
firm bay
addit major industri headwind creat
roadblock path creat next gener
valu estim rel base case scenario
analysi show moder varianc henc medium
uncertainti rate import driver valuat
far humira unknown pressur biosimilar
competit humira weigh certainti bull
case assum annual declin humira post
patent loss longer exclus period bear
case assum much rapid declin start
believ support narrow moat base
patent-protect drug intellectu intang
power salesforc case drug firm
core moat lie portfolio patent-protect
drug howev unlik pharma peer
tend carri wide moat one drug humira repres
major sale profit
greater result emerg brand
competit humira immedi term potenti
gener biosimilar threat time frame
believ excess return like persist year
certain outlook
would need wide-moat rate model
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
drug particular fda grown increasingli
risk-sensit approv safe drug drug
highli need area like cancer insur compani
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern around world
evalu compar effect program
aggress price negoti increas bar
need futur innov
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
support strong dividend yield
act valuat support cash flow support
dividend look secur next year
increas entrench blood cancer
bode well growth price power remain
solid therapeut area pharmaceut
osever pipelin drug immunolog
mechan action similar drug alreadi
approv take away first mover advantag
oth high profit margin humira like caus
amplifi impact earn sale lost
jak pathway help mitig
oth price power hepat drug erod
significantli past year may put
pressur next gener hepat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
despit high depend one key drug hold
strong balanc produc robust cash flow
next sever year recent acquisit
increas debt ebitda ratio time
expect strong cash flow reduc acquisit
activ bring metric time
nevertheless increas pressur humira
competit brand biosimilar like put
financi pressur compani expect pipelin
asset help mitig headwind
similar drug firm face risk new
drug failur reimburs challeng new drug
drug price cut larg payer group grow
concentr humira sale make compani
significantli expos new competit threat
humira biosimilar new brand drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ manag team demonstr
standard stewardship fail acquisit attempt
shire concern believ new abrupt
treasuri law larg caus acquisit collaps
somewhat give manag pass nevertheless
billion break-up fee relat fail shire deal
show manag gaug polit landscap
correctli billion pharmacycl acquisit
appear fair use capit imbruvica reach
turn manag specif led
gonzalez join abbott held mani
manageri post throughout career firm
howev recent led drug group start juli
brief retir rel short tenur
key field drug commerci develop
concern execut go well
leadership back gonzalez cfo
abbott year background
licens acquisit help need
redeploy strong cash flow humira
acquisit partner augment compani
retir leav void expect
replac intern candid
ceo/chairman board/
repres date owner name posit common share held report holder issuer
va collegeamerica inv co amer
va collegeamerica gr fd amer
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pfizer settl humira patent reduc
likelihood at-risk launch
increas fair valu estim
follow humira licens agreement
allow access market
biosimilar version humira novemb
announc expect launch
biosimilar humira at-risk time close
howev follow announc at-risk launch
look unlik strong patent protect
develop around humira proven
difficult penetr initi expect
typic noncomposition-of-matt patent hold
gener competit howev case complex
humira biolog structur larg amount
addit noncomposition-of-matt patent make
case at-risk launch stronger addit year
exclus drive fair valu estim
provid year strong cash flow
expect use help fund research
develop next-gener drug support firm
narrow moat howev expect signific declin
humira sale follow build-up biosimilar
competit start declin
project follow declin sever
biosimilar version humira like drive price
drug
abbvi post solid european humira biosimilar
price discount weigh growth outlook
report solid third-quart result lower
expens lead better-than-expect bottom-lin
growth expect major chang fair
valu estim base minor out-performance
view stock under-valued market like overli
concern humira biosimilar competit
appreci pipelin even though immunolog drug
humira total sale continu post steadi gain
expect biosimilar pressur begin caus
key pillar declin high concentr
profit humira like futur declin lead us
view compani moat narrow even though firm
strong develop pipelin steadi portfolio
beyond humira gain hepat drug mavyret
hematolog drug key growth driver led total
growth expect total growth rate slow
significantli european biosimilar pressur
humira start octob manag expect
intern discount includ countri without
biosimilar higher expect like
due high number simultan biosimilar launch
also expect biosimilar pressur late
ahead time frame announc settlement
biosimilar view at-risk launch
like addit pressur humira
expect bolu demand mavyret level
result minor growth drug next year
offset expect slow growth humira
mavyret believ hematolog drug
imbruvica venclexta continu post strong gain
new pipelin launch help stabil
busi expect recent launch endometriosi
drug orilissa like launch immunolog
drug risankizumab upadacitinib add three new major
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
